Liver Disease Treatment Market by Treatment Type and Disease Type: Global Opportunity Analysis and Industry Forecast, 2021-2030

The global liver disease treatment market was valued at $20,673.70 million in 2020, and is estimated to reach $36,455.70 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030. The liver is a vital organ of the body and has more than 500 functions and has primary functions such as bile production & excretion, excretion of bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins that are blood detoxification and purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal, and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to inheritance, such as hemochromatosis, hyperoxaluria, and Wilson’s disease.

Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions. For instance, hepatitis B is a liver disease caused by a virus called hepatitis B virus (HBV). This condition is treated using antiviral drugs and can also be prevented by use of vaccines. Furthermore, other drugs that are used in treatment of hepatitis include immunoglobulin. Similarly, liver cancer is treated by using chemotherapy drugs and targeted therapy. In addition, some autoimmune liver related disorders are treated with the use of corticosteroids. Furthermore, liver associated conditions require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection.

Swelling in the abdomen and legs, easy bruising, changes in the color of faeces & urine, and jaundice, or yellowing of the skin and eyes, are all common symptoms of liver disease. Imaging and liver function testing can both detect liver damage and aid in the diagnosis of liver diseases. The liver disease treatments majorly comprise of immunosuppressant’s, chemotherapy drugs, targeted therapy, vaccines, antiviral drugs, immunoglobulins, and corticosteroids. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders
Increase in alcohol consumption, obesity, unhealthy diets, unhealthy lifestyle due to increase stress, and rise in geriatric population are the major factors that drive the growth of the market. Rise in the consumption of alcohol is one of the major factors that leads to liver disorders. Alcohol alters the chemicals that break down scar tissue and eliminate it. This means that scar tissue accumulates in the liver and normal healthy cells are replaced by scar tissue. Thus, the liver is unable to function properly and may fail, resulting in death. Alcohol-related liver disease (ARLD) include alcoholic fatty liver disease, acute alcoholic hepatitis and alcoholic cirrhosis.

For instance, according to the National Center for Drug Abuse Statistics 2021, there were about 95.2 thousand alcohol-related deaths among which 31.08% were due to liver diseases. Alcoholic liver disease is the leading killer, which causes 19.1% of all alcohol-related deaths. Thus, such high mortality can be prevented by appropriate liver treatment at the right time, and thus boosts the growth of the market.

In addition, overweight and obesity is another major factor driven by rise in consumption of carbohydrate-based foods, packaged foods, poor eating habits, and unhealthy lifestyle among young generation as well adults thus leading to weight gain and further obesity. According to the World Health Organization (WHO), the majority of the world's population lives in countries where obesity and overweight people kills more people than persons who are underweight.

Furthermore, according to the World Obesity Federation that by 2025, approximately 2.7 billion adults would be overweight, over 1 billion will be obese, and 177 million adults will be extremely obese, if current trends continue. Fat accumulates in the liver as a result of being overweight or obese. This leads to chronic inflammation and scarring of the liver also known as cirrhosis. Thus, surge in obesity population is expected to boost the liver disease treatment market.

Moreover, increase in population especially the geriatric leads to rise in chronic diseases and may lead to liver dysfunction. Surge in diabetes, cardiovascular diseases, metabolic syndromes further lead to liver disorders. For instance, in March 2020, the Drug Controller General of India (DCGI) has approved Zydus Cadila's new drug application for saroglitazar, which is used to treat non-cirrhotic non-alcoholic steatohepatitis (NASH). NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. In advanced cirrhosis with liver failure, liver transplantation is the only treatment option. Thus, approval of such drugs and various government initiatives for liver disease awareness are anticipated to further drive the growth of the liver disease treatment market.

Increase in the liver disease treatment is majorly due to technological advancements in imaging, surge in drug discovery, novel treatments for the diseases, increase in R & D activities, and research funding by both private and public organizations. In addition, various government initiatives for awareness regarding the liver disorders is expected to boost the market growth.

The global liver disease treatment market is segmented into treatment type, disease type, and region. On the basis of treatment, the market is segregated into antiviral drugs, immunosuppressant’s, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy drugs. By disease type, it is categorized into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others (congenital hepatic fibrosis and biliary atresia).

The major players profiled in the report are AbbVie Inc., Abbott Laboratories, Astellas Pharma Inc., Bristol Myers Squibb, Eli Lilly and Company, F. Hoffman-LA Roche, Emergent BioSolutions (Cangene bioPharma), Gilead Sciences, Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), and Viatris Inc.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global liver disease treatment market to identify the prevailing opportunities.
This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Treatment Type

Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy

By Disease Type

Hepatitis
Autoimmune Diseases
Non-Alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

AbbVie Inc.
Abbott Laboratories
Astellas Pharma Inc.
Bristol Myers Squibb
Eli Lilly and Company
F. Hoffman-LA Roche
Emergent BioSolutions (Cangene bioPharma)
Gilead Sciences, Inc.,
Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
Viatris Inc.

Please note:

Online Access price format is valid for 60 days access. Printing is not enabled.
PDF Single and Enterprise price formats enable printing.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profile in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of liver diseases
3.5.1.2. Increased alcohol consumption and poor dietary habits
3.5.1.3. Surge in geriatric population
3.5.1.4. Increase in government and nongovernment awareness programs
3.5.2. Restraints
3.5.2.1. Stringent regulatory approvals related to liver disease treatment drugs and vaccines
3.5.2.2. Resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C
3.5.3. Opportunity
3.5.3.1. Presence of strong pipeline products
3.6. Impact analysis
3.7. Impact analysis of COVID-19 on the liver disease treatment market

CHAPTER 4: LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE

4.1. Overview
4.1.1. Market size and forecast
4.2. Antiviral drugs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Immunosuppressants
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Vaccines
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Immunoglobulins
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Corticosteroids
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Targeted therapy
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Chemotherapy
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

CHAPTER 5: LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE

5.1. Overview
5.1.1. Market size and forecast
5.2. Hepatitis
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Autoimmune diseases
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Non-alcoholic fatty liver disease (NAFLD)
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Cancer
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Genetic disorders
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Others
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country

CHAPTER 6: LIVER DISEASE TREATMENT MARKET, BY REGION

6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America liver disease treatment market, by treatment type
6.2.3. North America liver disease treatment market, by disease type
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. U.S. liver disease treatment market, by treatment type
6.2.4.1.2. U.S. liver disease treatment market, by disease type
6.2.4.2. Canada
6.2.4.2.1. Canada liver disease treatment market, by treatment type
6.2.4.2.2. Canada liver disease treatment market, by disease type
6.2.4.3. Mexico
6.2.4.3.1. Mexico liver disease treatment market, by treatment type
6.2.4.3.2. Mexico liver disease treatment market, by disease type
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe liver disease treatment market, by treatment type
6.3.3. Europe liver disease treatment market, by disease type
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Germany liver disease treatment market, by treatment type
6.3.4.1.2. Germany liver disease treatment market, by disease type
6.3.4.2. France
6.3.4.2.1. France liver disease treatment market, by treatment type
6.3.4.2.2. France liver disease treatment market, by disease type
6.3.4.3. UK
6.3.4.3.1. UK liver disease treatment market, by treatment type
6.3.4.3.2. UK liver disease treatment market, by disease type
6.3.4.4. Italy
6.3.4.4.1. Italy liver disease treatment market, by treatment type
6.3.4.4.2. Italy liver disease treatment market, by disease type
6.3.4.5. Spain
6.3.4.5.1. Spain liver disease treatment market, by treatment type
6.3.4.5.2. Spain liver disease treatment market, by disease type
6.3.4.6. Rest of Europe
6.3.4.6.1. Rest of Europe liver disease treatment market, by treatment type
6.3.4.6.2. Rest of Europe liver disease treatment market, by disease type
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific liver disease treatment market, by treatment type
6.4.3. Asia-Pacific liver disease treatment market, by disease type
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Japan liver disease treatment market, by treatment type
6.4.4.1.2. Japan liver disease treatment market, by disease type
6.4.4.2. China
6.4.4.2.1. China liver disease treatment market, by treatment type
6.4.4.2.2. China liver disease treatment market, by disease type
6.4.4.3. Australia
6.4.4.3.1. Australia liver disease treatment market, by treatment type
6.4.4.3.2. Australia liver disease treatment market, by disease type
6.4.4.4. India
6.4.4.4.1. India liver disease treatment market, by treatment type
6.4.4.4.2. India liver disease treatment market, by disease type
6.4.4.5. South Korea
6.4.4.5.1. South Korea liver disease treatment market, by treatment type
6.4.4.5.2. South Korea liver disease treatment market, by disease type
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Rest of Asia-Pacific liver disease treatment market, by treatment type
6.4.4.6.2. Rest of Asia-Pacific liver disease treatment market, by disease type
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA liver disease treatment market, by treatment type
6.5.3. LAMEA liver disease treatment market, by disease type
6.5.4. LAMEA liver disease treatment market, by country
6.5.4.1. Brazil
6.5.4.1.1. Brazil liver disease treatment market, by treatment type
6.5.4.1.2. Brazil liver disease treatment market, by disease type
6.5.4.2. Saudi Arabia
6.5.4.2.1. Saudi Arabia liver disease treatment market, by treatment type
6.5.4.2.2. Saudi Arabia liver disease treatment market, by disease type
6.5.4.3. South Africa
6.5.4.3.1. South Africa liver disease treatment market, by treatment type
6.5.4.3.2. South Africa liver disease treatment market, by disease type
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Rest of LAMEA liver disease treatment market, by treatment type
6.5.4.4.2. Rest of LAMEA liver disease treatment market, by disease type

CHAPTER 7: COMPANY PROFILES

7.1. ABBVIE INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. ABBOTT LABORATORIES
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. ASTELLAS PHARMA INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. BRISTOL-MYERS SQUIBB
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. ELI LILLY AND COMPANY
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. F. HOFFMANN-LA ROCHE AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. GILEAD SCIENCES, INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. MERCK & CO. INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. VIATRIS INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

List of Tables

TABLE 01. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 02. ANTIVIRAL DRUGS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 03. IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 04. VACCINES MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 05. IMMUNOGLOBULINS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 06. CORTICOSTEROIDS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 07. TARGETED THERAPY MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 08. CHEMOTHERAPY MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 09. LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 10. LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY REGION, 2020-2030 ($MILLION)
TABLE 11. LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020-2030($MILLION)
TABLE 12. LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), BY REGION, 2020-2030($MILLION)
TABLE 13. LIVER DISEASE TREATMENT MARKET FOR CANCER, BY REGION, 2020-2030($MILLION)
TABLE 14. LIVER DISEASE TREATMENT MARKET FOR GENETIC DISORDERS, BY REGION, 2020-2030($MILLION)
TABLE 15. LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 16. LIVER DISEASE TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17. NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 18. NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 19. NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 20. U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 21. U.S. LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 22. CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 23. CANADA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 24. MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 25. MEXICO LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 26. EUROPE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 27. EUROPE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 28. EUROPE LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 29. GERMANY LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 30. GERMANY LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 31. FRANCE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 32. FRANCE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 33. UK LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 34. UK LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 35. ITALY LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 36. ITALY LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 37. SPAIN LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 38. SPAIN LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 39. REST OF EUROPE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 40. REST OF EUROPE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 41. ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 42. ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 43. ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 44. JAPAN LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 45. JAPAN LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 46. CHINA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 47. CHINA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 48. AUSTRALIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 49. AUSTRALIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 50. INDIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 51. INDIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 52. SOUTH KOREA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 53. SOUTH KOREA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 55. REST OF ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 56. LAMEA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 57. LAMEA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 58. LAMEA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 59. BRAZIL LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 60. BRAZIL LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 61. SAUDI ARABIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 62. SAUDI ARABIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 63. SOUTH AFRICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 64. SOUTH AFRICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 65. REST OF LAMEA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 66. REST OF LAMEA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 67. ABBVIE: COMPANY SNAPSHOT
TABLE 68. ABBVIE: PRODUCT SEGMENTS
TABLE 69. ABBVIE: PRODUCT PORTFOLIO
TABLE 70. ABBVIE: KEY DEVELOPMENTS
TABLE 71. ABBOTT: COMPANY SNAPSHOT
TABLE 72. ABBOTT: OPERATING SEGMENTS
TABLE 73. ABBOTT: PRODUCT PORTFOLIO
TABLE 74. ASTELLAS: COMPANY SNAPSHOT
TABLE 75. ASTELLAS: OPERATING SEGMENTS
TABLE 76. ASTELLAS: PRODUCT PORTFOLIO
TABLE 77. BRISTOL: COMPANY SNAPSHOT
TABLE 78. BRISTOL: PRODUCT SEGMENTS
TABLE 79. BRISTOL: PRODUCT PORTFOLIO
TABLE 80. LILLY: COMPANY SNAPSHOT
TABLE 81. LILLY: OPERATING SEGMENTS
TABLE 82. LILLY: PRODUCT PORTFOLIO
TABLE 83. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. EMERGENT SOLUTIONS: COMPANY SNAPSHOT
TABLE 85. EMERGENT SOLUTIONS: OPERATING SEGMENTS
TABLE 86. EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
TABLE 87. ROCHE: COMPANY SNAPSHOT
TABLE 88. ROCHE: PRODUCT SEGMENTS
TABLE 89. ROCHE: PRODUCT PORTFOLIO
TABLE 90. ROCHE: KEY DEVELOPMENTS
TABLE 91. GILEAD: COMPANY SNAPSHOT
TABLE 92. GILEAD: OERATING SEGMENT
TABLE 93. GILEAD: PRODUCT PORTFOLIO
TABLE 94. MERCK: COMPANY SNAPSHOT
TABLE 95. MERCK: OPERATING SEGMENTS
TABLE 96. MERCK: PRODUCT PORTFOLIO
TABLE 97. VIATRIS: COMPANY SNAPSHOT
TABLE 98. VIATRIS: OPERATING BUSINESS SEGMENTS
TABLE 99. VIATRIS: PRODUCT PORTFOLIO

List of Figures

FIGURE 01. GLOBAL LIVER DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07. HIGH BARGAINING POWER OF BUYERS
FIGURE 08. HIGH THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR ANTIVIRAL DRUGS, BY COUNTRY, 2020-2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2020-2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR VACCINES, BY COUNTRY, 2020-2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020-2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020-2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY COUNTRY, 2020-2030 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF FOR LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2030 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), BY COUNTRY, 2020-2030 (%)
FIGURE 23. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CANCER, BY COUNTRY, 2020-2030 (%)
FIGURE 24. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2020-2030 (%)
FIGURE 25. COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 26. ABBVIE: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. ABBVIE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 28. ABBOTT: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. ABBOTT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 31. ASTELLAS: NET SALES, 2018-2020 ($MILLION)
FIGURE 32. ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 33. ASTELLAS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34. BRISTOL: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. BRISTOL: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36. LILLY: NET SALES, 2018-2020 ($MILLION)
FIGURE 37. LILLY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 38. EMERGENT SOLUTIONS: NET SALES, 2019-2020 ($MILLION)
FIGURE 39. EMERGENT SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40. EMERGENT SOLUTIONS: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 41. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 42. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43. ROCHE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 44. GILEAD: NET SALES, 2018-2020 ($MILLION)
FIGURE 45. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 46. MERCK: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 47. MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 48. VIATRIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 49. VIATRIS: REVENUE SHARE, BY REGION, 2020 (%)

Companies Mentioned

AbbVie Inc.
Abbott Laboratories
Astellas Pharma Inc.
Bristol Myers Squibb
Eli Lilly and Company
F. Hoffman-LA Roche
Emergent BioSolutions (Cangene bioPharma)
Gilead Sciences, Inc.,
Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
Viatris Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic news articles and other related releases for market evaluation
Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

LOADING...

Table Information

Report Attribute	Details
No. of Pages	254
Published	December 2021
Forecast Period	2020 - 2030
Estimated Market Value ( USD ) in 2020	$ 20673.7 million
Forecasted Market Value ( USD ) by 2030	$ 36455.7 million
Compound Annual Growth Rate	5.8%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE Online Access		This is a single user license, allowing one user access to the product.	€3643EUR$3,712USD£3,046GBP
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5663EUR$5,769USD£4,734GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€10466EUR$10,663USD£8,750GBP

KEY BENEFITS FOR STAKEHOLDERS

KEY MARKET SEGMENTS

By Treatment Type

By Disease Type

By Region

KEY MARKET PLAYERS

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Liver Disease Treatment Market Report by Treatment Type, Disease Type, End User, and Region 2024-2032

Liver Disease Therapeutic Market Report by Therapy Type Disease Type End Users Regions and Company Analysis 2024-2032

Liver Diseases Therapeutics Global Market Report 2024

Liver Diseases Therapeutics Market by Treatment, End User - Global Forecast 2025-2030